Literature DB >> 27366236

Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration.

Christiane Schneider-Gold1, Marco Krenzer1, Erdmute Klinker2, Behrouz Mansouri-Thalegani2, Wolfgang Müllges1, Klaus V Toyka1, Ralf Gold3.   

Abstract

OBJECTIVES: The goal of this study was to analyze safety and assess the efficacy of standard plasma exchange (PE) compared with immunoadsorption (IA) alone, or an alternating combination of both in deteriorating myasthenia gravis (MG).
METHODS: A total of 72 patients with MG who had received PE procedures for treatment of severe deterioration were retrospectively analyzed. They received either five cycles of PE (1-1.5 plasma volumes), or five cycles of IA in line with plasma separation, or a sequential alternating procedure of one cycle of PE followed by two cycles of IA, which was repeated once or more if needed.
RESULTS: A total of 19 patients received PE, 24 patients IA, and 29 the alternating combination therapy. All groups were equally distributed by sex and mean MG score before treatment. The number of treatment cycles and days on therapy did not differ between the groups. Mean MG scores at discharge were 3.0 (PE), 1.8 (IA) and 1.6 (combination) (p = 0.028 for combination versus PE). Inpatient time was 30.7 days (PE), 22.3 days (IA) and 20.0 days in combination therapy (p < 0.05 for combination versus PE). Side effects such as allergic reactions or hypocoagulability were significantly more frequent in the PE group (37% in PE versus 4% in IA and 3.6% in the alternating combination, p < 0.05).
CONCLUSION: Semiselective IA in combination with PE, and to a lesser extent IA alone, was associated with a shorter hospital stay and more pronounced reduction of the MG score than PE.

Entities:  

Keywords:  immunoadsorption; myasthenia gravis; myasthenic crisis; plasma exchange; therapy

Year:  2016        PMID: 27366236      PMCID: PMC4916519          DOI: 10.1177/1756285616637046

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  21 in total

1.  Long-term treatment of myasthenia gravis with immunoadsorption.

Authors:  Martin Haas; Norbert Mayr; Josef Zeitlhofer; Andreas Goldammer; Kurt Derfler
Journal:  J Clin Apher       Date:  2002       Impact factor: 2.821

2.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

3.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.

Authors:  Jun-Feng Liu; Wei-Xin Wang; Jun Xue; Chong-Bo Zhao; Huai-Zhou You; Jia-Hong Lu; Yong Gu
Journal:  Ther Apher Dial       Date:  2010-04       Impact factor: 1.762

5.  alpha-Bungarotoxin and anti-acetylcholine receptor antibody binding to the human acetylcholine receptor.

Authors:  A Vincent; J Newsom-Davis
Journal:  Adv Cytopharmacol       Date:  1979

6.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

7.  Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.

Authors:  M Takamori; T Maruta
Journal:  Ther Apher       Date:  2001-10

8.  A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.

Authors:  Wolfgang Köhler; Christoph Bucka; Reinhard Klingel
Journal:  J Clin Apher       Date:  2011-11-17       Impact factor: 2.821

9.  Myasthenia gravis: passive transfer from man to mouse.

Authors:  K V Toyka; D B Brachman; A Pestronk; I Kao
Journal:  Science       Date:  1975-10-24       Impact factor: 47.728

Review 10.  Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.

Authors:  Paraskevi Zisimopoulou; George Lagoumintzis; Kalliopi Kostelidou; Kalliopi Bitzopoulou; Gregory Kordas; Nikolaos Trakas; Konstantinos Poulas; Socrates J Tzartos
Journal:  J Neuroimmunol       Date:  2008-07-29       Impact factor: 3.478

View more
  11 in total

1.  Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.

Authors:  Sotaro Mori; Takuji Kurimoto; Kaori Ueda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2018-05-25       Impact factor: 2.447

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study.

Authors:  Shaoying Tan; Tsz Kin Ng; Quangang Xu; Mo Yang; Yuan Zhuang; Jie Zhao; Huanfen Zhou; Da Teng; Shihui Wei
Journal:  Ther Adv Neurol Disord       Date:  2020-08-21       Impact factor: 6.570

4.  CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.

Authors:  Marc Pawlitzki; Catherine M Sweeney-Reed; Sven G Meuth; Dirk Reinhold; Jens Neumann
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

Review 5.  Understanding the burden of refractory myasthenia gravis.

Authors:  Christiane Schneider-Gold; Tim Hagenacker; Nico Melzer; Tobias Ruck
Journal:  Ther Adv Neurol Disord       Date:  2019-03-01       Impact factor: 6.570

Review 6.  Advances and challenges in the treatment of myasthenia gravis.

Authors:  Christiane Schneider-Gold; Nils Erik Gilhus
Journal:  Ther Adv Neurol Disord       Date:  2021-12-21       Impact factor: 6.570

7.  Total Plasma Exchange in Neuromuscular Junction Disorders-A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis.

Authors:  Andreas Totzeck; Michael Jahn; Benjamin Stolte; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

8.  Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

Authors:  Frank Hoffmann; Andrea Kraft; Franz Heigl; Erich Mauch; Jürgen Koehler; Lutz Harms; Tania Kümpfel; Wolfgang Köhler; Sven Ehrlich; Antonios Bayas; Julia Weinmann-Menke; Carolin Beuker; Karl-Heinz Henn; Ilya Ayzenberg; Gisa Ellrichmann; Kerstin Hellwig; Reinhard Klingel; Cordula Marie Fassbender; Harald Fritz; Torsten Slowinski; Horst Weihprecht; Marcus Brand; Thomas Stiegler; Jan Galle; Sebastian Schimrigk
Journal:  Ther Adv Neurol Disord       Date:  2018-05-28       Impact factor: 6.570

9.  Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.

Authors:  Johannes Dorst; Tanja Fangerau; Daniela Taranu; Pia Eichele; Jens Dreyhaupt; Sebastian Michels; Joachim Schuster; Albert C Ludolph; Makbule Senel; Hayrettin Tumani
Journal:  EClinicalMedicine       Date:  2019-11-14

10.  Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.

Authors:  Mark Lipphardt; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.